UK markets closed

Inventiva S.A. (IVEVF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.67000.0000 (0.00%)
At close: 01:36PM EST
Full screen
Trade prices are not sourced from all markets
Previous close3.6700
Open3.6650
BidN/A x N/A
AskN/A x N/A
Day's range3.6700 - 3.6700
52-week range3.6650 - 5.1300
Volume3,000
Avg. volume0
Market cap189.543M
Beta (5Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)-2.0500
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.55
  • Globe Newswire

    Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

    Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million2, and long-term deposit at €9.0 million3 as of December 31, 2023, compared to €86.7 million, €1.0 million, and €0.7 million respectively, as of December 31, 2022 Receipt on January 18, 2024 of the second tranche of €25 million under the EIB loan agreement4Estimated cash runway until the beginning of the third quarter of 20245Pati

  • GlobeNewswire

    Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

    Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.Under the liquidity contract granted to Kep

  • Globe Newswire

    Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

    Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH.This second tranche carries an interest rate of 7% annually and has a maturity of 3 years and a repayment in fine which is expected to occur after the anticipated publication of the results of the NATiV3 Phase III trial evaluating lanifibranor in patients with NASH, expected in the first half of 2026.The €25 million supports Inventiva’s estimated